WO2001062979A3 - Dentification of partial agonists of the a2a adenosine receptor - Google Patents

Dentification of partial agonists of the a2a adenosine receptor Download PDF

Info

Publication number
WO2001062979A3
WO2001062979A3 PCT/US2001/005831 US0105831W WO0162979A3 WO 2001062979 A3 WO2001062979 A3 WO 2001062979A3 US 0105831 W US0105831 W US 0105831W WO 0162979 A3 WO0162979 A3 WO 0162979A3
Authority
WO
WIPO (PCT)
Prior art keywords
dentification
adenosine receptor
partial agonists
cvt
partial
Prior art date
Application number
PCT/US2001/005831
Other languages
French (fr)
Other versions
WO2001062979A2 (en
Inventor
Luiz Belardinelli
Brent Blackburn
Zhenhai Gao
Original Assignee
Cv Therapeutics Inc
Luiz Belardinelli
Brent Blackburn
Zhenhai Gao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc, Luiz Belardinelli, Brent Blackburn, Zhenhai Gao filed Critical Cv Therapeutics Inc
Priority to CA002439222A priority Critical patent/CA2439222C/en
Priority to AU2001238665A priority patent/AU2001238665A1/en
Publication of WO2001062979A2 publication Critical patent/WO2001062979A2/en
Publication of WO2001062979A3 publication Critical patent/WO2001062979A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging; in particular, compounds CVT-3033 and CVT-3146 were used.
PCT/US2001/005831 2000-02-23 2001-02-23 Dentification of partial agonists of the a2a adenosine receptor WO2001062979A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002439222A CA2439222C (en) 2000-02-23 2001-02-23 Identification of partial agonists of the a2a adenosine receptor
AU2001238665A AU2001238665A1 (en) 2000-02-23 2001-02-23 Method of identifying partial agonists of the a2a receptor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18429600P 2000-02-23 2000-02-23
US60/184,296 2000-02-23
US21987600P 2000-07-21 2000-07-21
US60/219,876 2000-07-21

Publications (2)

Publication Number Publication Date
WO2001062979A2 WO2001062979A2 (en) 2001-08-30
WO2001062979A3 true WO2001062979A3 (en) 2002-02-28

Family

ID=26880004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/005831 WO2001062979A2 (en) 2000-02-23 2001-02-23 Dentification of partial agonists of the a2a adenosine receptor

Country Status (4)

Country Link
US (6) US20020012946A1 (en)
AU (1) AU2001238665A1 (en)
CA (2) CA2439222C (en)
WO (1) WO2001062979A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045519B2 (en) 1999-06-22 2015-06-02 Gilead Sciences, Inc. N-pyrazole A2A receptor agonists
US9085601B2 (en) 2006-02-03 2015-07-21 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US9289446B2 (en) 2002-07-29 2016-03-22 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2492855C (en) * 2002-07-29 2012-09-18 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
SG173924A1 (en) * 2004-01-27 2011-09-29 Gilead Palo Alto Inc Myocardial perfusion imaging using adenosine receptor agonists
EP1708721B1 (en) * 2004-01-27 2013-08-07 Gilead Sciences, Inc. Myocardial perfusion imaging using adenosine receptor agonists
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7655636B2 (en) * 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
US20060159621A1 (en) * 2005-01-12 2006-07-20 Barrett Richard J Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP2056834B1 (en) * 2006-09-01 2012-08-29 Gilead Sciences, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
EP2187883A2 (en) * 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
MX2011003168A (en) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods.
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
CA2809362C (en) 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
ES2890529T3 (en) 2012-05-16 2022-01-20 Stemline Therapeutics Inc Cancer vaccines targeting cancer stem cells
US10568483B2 (en) * 2014-12-12 2020-02-25 Irobot Corporation Cleaning system for autonomous robot

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0354638A2 (en) * 1988-08-11 1990-02-14 Medco Research Inc Use of adenosine and its derivatives in diagnosis
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
WO2000078779A2 (en) * 1999-06-22 2000-12-28 Cv Therapeutics, Inc. N-pyrazole a2a receptor agonists
WO2000078778A2 (en) * 1999-06-22 2000-12-28 Cv Therapeutics, Inc. C-pyrazole a2a receptor agonists

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (en) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogous process for the preparation of 2-substituted adenosine derivatives or acid addition salts thereof.
BE787064A (en) 1971-08-03 1973-02-01 Philips Nv MAGNETIC DEVICE CONTAINING DOMAINS
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4089959A (en) 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
US4120947A (en) 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
SE7810946L (en) 1978-10-20 1980-04-21 Draco Ab METHOD OF TREATING CHRONIC OBSTRUCTIVE AIR DISEASE
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (en) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 2-alkinyladenosine and antihypertensive
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
JPH0638525B2 (en) * 1987-05-06 1994-05-18 株式会社半導体エネルギ−研究所 Method for manufacturing superconducting device
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE3831430A1 (en) 1988-09-15 1990-03-22 Bayer Ag SUBSTITUTED 4-HETEROCYCLYLOXIMINO-PYRAZOLIN-5-ONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL
EP0444196B1 (en) 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
IT1229195B (en) 1989-03-10 1991-07-25 Poli Ind Chimica Spa XANTHINIC DERIVATIVES WITH BRONCODILATORY ACTIVITY AND THEIR THERAPEUTIC APPLICATIONS.
CA2035038C (en) 1989-06-20 1998-12-29 Toyofumi Yamaguchi Synthetic intermediates of 2-alkynyladenosines, processes for preparing the synthetic intermediates, processes for preparing 2-alkynyladenosines utilizing the synthetic intermediates, and stable 2-alkynyladenosine derivatives
US5032252A (en) 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (en) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (en) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med METHOD FOR DESCRIBING ANTIBODY (AB) DIRECTORIES AND T CELL RECEPTORS (TCR) IN THE INDIVIDUAL'S IMMUNE SYSTEM.
JP2740362B2 (en) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 Stable solid 2-octynyl adenosine and process for its preparation
JP3053908B2 (en) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 2-alkynyl adenosine derivatives
JP2916305B2 (en) 1991-07-31 1999-07-05 株式会社タダノ Work machine interlock device
US5516894A (en) 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (en) 1992-04-24 1995-10-11 Gloria Cristalli ADENOSINE DERIVATIVES FOR ACTIVITY A2 AGONIST
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
JPH08500967A (en) 1992-06-12 1996-02-06 ガーヴァン インスティチュート オブ メディカル リサーチ DNA sequences encoding human A1, A2a and A2b adenosine receptors
US5705491A (en) 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
CA2112031A1 (en) 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
EP0698607B1 (en) 1994-02-23 2002-05-29 Kyowa Hakko Kogyo Kabushiki Kaisha Xanthine derivative
US5704491A (en) 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
EP1014995A4 (en) 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc Compositions and methods for preventing restenosis following revascularization procedures
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
CA2316994A1 (en) 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
EP1208100B1 (en) 1999-08-31 2003-04-02 Vanderbilt University Selective antagonists of a2b adenosine receptors
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
ATE459598T1 (en) 2001-05-14 2010-03-15 Novartis Ag SULFONAMIDE DERIVATIVES
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
ATE520694T1 (en) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2B ADENOSINE RECEPTOR ANTAGONISTS
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1494685B1 (en) 2002-04-18 2008-12-31 Cv Therapeutics, Inc. Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
CA2492855C (en) 2002-07-29 2012-09-18 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
EP1708721B1 (en) 2004-01-27 2013-08-07 Gilead Sciences, Inc. Myocardial perfusion imaging using adenosine receptor agonists
AU2005295654B2 (en) 2004-10-15 2011-04-14 Gilead Sciences, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7655636B2 (en) 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
US20060159621A1 (en) 2005-01-12 2006-07-20 Barrett Richard J Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
AU2007212542B2 (en) 2006-02-03 2013-01-31 Gilead Sciences, Inc. Process for preparing an A2A-Adenosine receptor agonist and its polymorphs
US7528617B2 (en) * 2006-03-07 2009-05-05 Testmetrix, Inc. Apparatus having a member to receive a tray(s) that holds semiconductor devices for testing
CA2655310A1 (en) 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
EP2056834B1 (en) 2006-09-01 2012-08-29 Gilead Sciences, Inc. Methods and compositions for increasing patient tolerability during myocardial imaging methods
US20090081120A1 (en) 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
KR20140041965A (en) 2007-05-17 2014-04-04 씨브이 쎄러퓨틱스, 인코포레이티드 Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
MX2011003168A (en) 2008-09-29 2011-05-19 Gilead Sciences Inc Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0354638A2 (en) * 1988-08-11 1990-02-14 Medco Research Inc Use of adenosine and its derivatives in diagnosis
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
WO2000078779A2 (en) * 1999-06-22 2000-12-28 Cv Therapeutics, Inc. N-pyrazole a2a receptor agonists
WO2000078778A2 (en) * 1999-06-22 2000-12-28 Cv Therapeutics, Inc. C-pyrazole a2a receptor agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAO ZHENHAI ET AL: "Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 298, no. 1, July 2001 (2001-07-01), pages 209 - 218, XP001030724, ISSN: 0022-3565 *
GLOVER DAVID K ET AL: "Characterization of a new, highly selective adenosine A2A receptor agonist with potential use in pharmacologic stress perfusion imaging.", CIRCULATION, vol. 110, no. 18 SUPPL., 2 November 1999 (1999-11-02), 72nd Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 7-10, 1999, pages I.311, XP001030720, ISSN: 0009-7322 *
ISKANDRIAN ABDULMASSIH S: "Adenosine myocardial perfusion imaging.", JOURNAL OF NUCLEAR MEDICINE, vol. 35, no. 4, 1994, pages 734 - 736, XP002180418, ISSN: 0161-5505 *
XU JIANG ET AL: "Coronary vasodilation by a short acting, low affinity A2A adenosine receptor agonist in anesthetized closed chest dogs: A second generation of coronary artery pharmacologic "stressor".", CIRCULATION, vol. 102, no. 18 Supplement, 31 October 2000 (2000-10-31), Abstracts from Scientific Sessions 2000;New Orleans, Louisiana, USA; November 12-15, 2000, pages II.810, XP001030765, ISSN: 0009-7322 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045519B2 (en) 1999-06-22 2015-06-02 Gilead Sciences, Inc. N-pyrazole A2A receptor agonists
US9289446B2 (en) 2002-07-29 2016-03-22 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US9085601B2 (en) 2006-02-03 2015-07-21 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs

Also Published As

Publication number Publication date
AU2001238665A1 (en) 2001-09-03
US7582617B2 (en) 2009-09-01
US20020012946A1 (en) 2002-01-31
CA2439222C (en) 2009-07-14
US20040137533A1 (en) 2004-07-15
US8071566B2 (en) 2011-12-06
US20150023867A1 (en) 2015-01-22
US20120251440A1 (en) 2012-10-04
CA2439222A1 (en) 2001-08-30
CA2671940A1 (en) 2001-08-30
US8536150B2 (en) 2013-09-17
WO2001062979A2 (en) 2001-08-30
US20050175535A1 (en) 2005-08-11
US20090317331A1 (en) 2009-12-24
US9163057B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
WO2001062979A3 (en) Dentification of partial agonists of the a2a adenosine receptor
CA2397772A1 (en) Method for determining the response to cancer therapy
NO20033481D0 (en) Integrated reactors, as well as process for making and using the same
ZA200100900B (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists.
EP1467756A4 (en) Methods for using anti-muc18 antibodies
SG116439A1 (en) System and method for determining specific rquirements from general requirements documents.
AU2002303270A1 (en) System, method, and software for identifying historically related legal opinions
IT1317757B1 (en) METHOD FOR THE PREPARATION OF HYDROGENATED HYDROCARBONS.
NO20021695L (en) 5- (2-Substituted-5-heterocycylsulfonylpyrid-3-yl) dihydropyrazolo [4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors
AU2001226354A1 (en) Fixative system, method and composition for biological testing
HK1031399A1 (en) Process for synthesizing cox-2 inhibitors.
ZA200210042B (en) Method for enhancing sustainability.
EG23299A (en) Process for preparing 1-octene.
WO2001087295A8 (en) Methods for decreasing cell proliferation based on (3r, 4r)-δ8-tetrahydrocannabinol-11-oic acids
HK1053839A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
ZA200402472B (en) Method for preparing benzenesulfonyl compounds.
WO2001060350A3 (en) Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
NO995348D0 (en) Slide assembly, and method for using it
WO2006104761A3 (en) Unique sequence hybridization probes (usp)
WO2004063710A9 (en) Mark-pap system (method, kit, solution & accessories) processes for producing and using the same
EP1377307A4 (en) Anti-gpe antibodies, their uses, and analytical methods for gpe
WO2003087051A3 (en) Methods for identifying allosteric sites
NO20022664L (en) Reaction rod for vehicles, and jig as well as process for making the reaction rod
MXPA03008343A (en) Agents for measuring pyrimidine metabolizability.
AU2002220346A1 (en) Method for determination of the fertility of mammals, in particular of man

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2439222

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP